# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a...
UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:TMCI) with a Neutral and raises the price target fro...
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and lowers the price ...
The Company continues to expect Adjusted EBITDA to improve approximately 50% compared to full-year 2023.*
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimat...
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price ...
Morgan Stanley analyst Drew Ranieri maintains Treace Medical Concepts (NASDAQ:TMCI) with a Equal-Weight and raises the price...